Rigrodsky & Long, P.A. Announces Investigation Of Trius Therapeutics, Inc. Buyout

Business Wirevia The Motley Fool
Updated

Rigrodsky & Long, P.A. Announces Investigation Of Trius Therapeutics, Inc. Buyout

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.:

  • Do you own shares of Trius Therapeutics, Inc. (NASDAQ GM:TSRX)?

  • Did you purchase any of your shares prior to July 30, 2013?

  • Do you think the proposed buyout price is too low?

  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Trius Therapeutics, Inc. ("Trius" or the "Company") (NASDAQ GM: TSRX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Cubist Pharmaceuticals, Inc. ("Cubist") (NASDAQ GS: CBST) in a transaction valued at approximately $818 million.


Click here to learn more: http://www.rigrodskylong.com/investigations/trius-therapeutics-inc-tsrx.

Under the terms of the agreement, public shareholders of Trius will receive $13.50 per share in cash for each share of Trius they own. In addition to the cash consideration, Trius shareholders would also receive one Contingent Value Right for each Trius share they own, which could yield additional cash consideration of up to $2.00 per share.

The investigation concerns whether Trius's board of directors failed to adequately shop the Company and obtain the best possible value for Trius's shareholders before entering into an agreement with Cubist. According to Yahoo! Finance, at least one analyst has set a price target for Trius stock at $20.00 per share.

If you own the common stock of Trius and purchased your shares before July 30, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth Rigrodsky or Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/trius-therapeutics-inc-tsrx.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.



Rigrodsky & Long, P.A.
Seth Rigrodsky
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
info@rl-legal.com
http://www.rigrodskylong.com

KEYWORDS: United States North America Delaware

INDUSTRY KEYWORDS:

The article Rigrodsky & Long, P.A. Announces Investigation Of Trius Therapeutics, Inc. Buyout originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement